These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20812725)

  • 1. 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
    Rose TE; Morisseau C; Liu JY; Inceoglu B; Jones PD; Sanborn JR; Hammock BD
    J Med Chem; 2010 Oct; 53(19):7067-75. PubMed ID: 20812725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
    Kim IH; Tsai HJ; Nishi K; Kasagami T; Morisseau C; Hammock BD
    J Med Chem; 2007 Oct; 50(21):5217-26. PubMed ID: 17894481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.
    Burmistrov V; Morisseau C; Danilov D; Harris TR; Dalinger I; Vatsadze I; Shkineva T; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5514-9. PubMed ID: 26520661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.
    Burmistrov V; Morisseau C; Harris TR; Butov G; Hammock BD
    Bioorg Chem; 2018 Feb; 76():510-527. PubMed ID: 29310082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adamantyl thioureas as soluble epoxide hydrolase inhibitors.
    Burmistrov V; Morisseau C; Pitushkin D; Karlov D; Fayzullin RR; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2018 Jul; 28(13):2302-2313. PubMed ID: 29803731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally bioavailable potent soluble epoxide hydrolase inhibitors.
    Hwang SH; Tsai HJ; Liu JY; Morisseau C; Hammock BD
    J Med Chem; 2007 Aug; 50(16):3825-40. PubMed ID: 17616115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.
    Burmistrov V; Morisseau C; Lee KS; Shihadih DS; Harris TR; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2014 May; 24(9):2193-7. PubMed ID: 24685540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
    Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
    Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
    Kim IH; Heirtzler FR; Morisseau C; Nishi K; Tsai HJ; Hammock BD
    J Med Chem; 2005 May; 48(10):3621-9. PubMed ID: 15887969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.
    Ulu A; Appt S; Morisseau C; Hwang SH; Jones PD; Rose TE; Dong H; Lango J; Yang J; Tsai HJ; Miyabe C; Fortenbach C; Adams MR; Hammock BD
    Br J Pharmacol; 2012 Mar; 165(5):1401-12. PubMed ID: 21880036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
    Morisseau C; Newman JW; Tsai HJ; Baecker PA; Hammock BD
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5439-44. PubMed ID: 16908134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
    Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
    Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.
    Burmistrov V; Morisseau C; Karlov D; Pitushkin D; Vernigora A; Rasskazova E; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127430. PubMed ID: 32736212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation.
    Liu JY; Tsai HJ; Hwang SH; Jones PD; Morisseau C; Hammock BD
    Br J Pharmacol; 2009 Jan; 156(2):284-96. PubMed ID: 19154430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.
    Shen HC; Ding FX; Wang S; Deng Q; Zhang X; Chen Y; Zhou G; Xu S; Chen HS; Tong X; Tong V; Mitra K; Kumar S; Tsai C; Stevenson AS; Pai LY; Alonso-Galicia M; Chen X; Soisson SM; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
    J Med Chem; 2009 Aug; 52(16):5009-12. PubMed ID: 19645482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
    Anandan SK; Webb HK; Chen D; Wang YX; Aavula BR; Cases S; Cheng Y; Do ZN; Mehra U; Tran V; Vincelette J; Waszczuk J; White K; Wong KR; Zhang LN; Jones PD; Hammock BD; Patel DV; Whitcomb R; MacIntyre DE; Sabry J; Gless R
    Bioorg Med Chem Lett; 2011 Feb; 21(3):983-8. PubMed ID: 21211973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models.
    Liu JY; Lin YP; Qiu H; Morisseau C; Rose TE; Hwang SH; Chiamvimonvat N; Hammock BD
    Eur J Pharm Sci; 2013 Mar; 48(4-5):619-27. PubMed ID: 23291046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
    Jones PD; Tsai HJ; Do ZN; Morisseau C; Hammock BD
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5212-6. PubMed ID: 16870439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.
    Tsai HJ; Hwang SH; Morisseau C; Yang J; Jones PD; Kasagami T; Kim IH; Hammock BD
    Eur J Pharm Sci; 2010 Jun; 40(3):222-38. PubMed ID: 20359531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.
    Liu JY; Tsai HJ; Morisseau C; Lango J; Hwang SH; Watanabe T; Kim IH; Hammock BD
    Biochem Pharmacol; 2015 Dec; 98(4):718-31. PubMed ID: 26494425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.